Conyers advised SELLAS Life Sciences Group Ltd. on the merger of the businesses of SELLAS and Galena Biopharma, Inc. (“Galena”). Upon completion of the merger, Galena was renamed SELLAS Life Sciences Group, Inc. (“SELLAS Inc.”), and now features a late-stage pipeline led by novel immunotherapies targeting a broad range of indications in hematologic and solid malignant cancers. SELLAS Inc. commenced trading on the Nasdaq Capital Market on 2 January 2018, under the ticker symbol “SLS”.
Director Guy Cooper led the Conyers team, which also included Director and Chairman Christian Luthi and Associate Victor Richards.
